Filing Details
- Accession Number:
- 0000899243-18-025322
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-09-26 19:01:40
- Reporting Period:
- 2018-09-24
- Accepted Time:
- 2018-09-26 19:01:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1631574 | Wave Life Sciences Ltd. | WVE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1657709 | Chris Francis | C/O Wave Life Sciences Ltd., 733 Concord Ave. Cambridge MA 02138 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2018-09-24 | 1,032 | $2.48 | 23,109 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2018-09-24 | 1,032 | $56.00 | 22,077 | No | 4 | S | Direct | |
Ordinary Shares | Acquisiton | 2018-09-25 | 10,543 | $2.48 | 32,620 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2018-09-25 | 10,543 | $56.00 | 22,077 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Share Option (right to buy) | Disposition | 2018-09-24 | 1,032 | $0.00 | 1,032 | $2.48 |
Ordinary Shares | Share Option (right to buy) | Disposition | 2018-09-25 | 10,543 | $0.00 | 10,543 | $2.48 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
51,540 | 2025-03-10 | No | 4 | M | Direct | |
40,997 | 2025-03-10 | No | 4 | M | Direct |
Footnotes
- The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.
- The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.